CyclopharmASX:CYC +10.87%45 Receivables Turnover is 0.02 as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 116 Medical Distribution companies, Cyclopharm ranks worse than 84.48% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cyclopharm's Revenue for the
six
months ended in Dec. 2025 was A$0.17 Mil. Cyclopharm's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$7.72 Mil.
Hence, Cyclopharm's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.02.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cyclopharm Receivables Turnover Related Terms
Cyclopharm Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYC vs MCK, CAH, COR: Receivables Turnover Comparison
For the Medical Distribution subindustry, Cyclopharm's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a Receivables Turnover of 0.02 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #98 out of 116 companies in the Medical Distribution industry, placing it in the top 84.5%.
Is Cyclopharm's Receivables Turnover too high?
Cyclopharm's current Receivables Turnover is 0.02. The Medical Distribution industry median Receivables Turnover is 4.55. Cyclopharm's value of 0.02 is 99.6% below this industry median. Based on the distribution chart, Cyclopharm ranks #98 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Receivables Turnover compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #98 out of 116 companies for Receivables Turnover. This places Cyclopharm in the lower half of its industry. The industry median Receivables Turnover is 4.55. Cyclopharm's value of 0.02 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyclopharm's current Receivables Turnover of 0.02 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Receivables Turnover is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.51 — trading 38.6% below its estimated fair value. The current Receivables Turnover is 0.02 and 99.6% below the Medical Distribution industry median of 4.55. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Receivables Turnover is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.51 is trading 38.6% below its estimated GF Value™ of A$0.83.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Receivables Turnover: 0.02
GF Value™: A$0.83 vs. price of A$0.51 (38.6% below fair value)
Industry Position: 99.6% below the Medical Distribution median (#98 of 116)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score
Get the complete analysis for ASX:CYC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
